Ionis Pharmaceuticals(NASDAQ) IONS

Ionis makes medicines that target RNA to treat people with serious and rare diseases. These treatments help by changing how the body produces proteins to fix the root cause of a condition. The company focuses on helping patients with heart, brain, and metabolic health issues.

What Ionis Sells

• Neurological Medicines: Treatments like SPINRAZA for spinal muscular atrophy and QALSODY for ALS, which help patients manage progressive nerve and muscle damage.
• Cardiometabolic Medicines: Drugs such as TRYNGOLZA and WAINUA that lower fats in the blood or reduce protein buildup to prevent organ damage.
• Rare Disease Therapies: Specialized injections like DAWNZERA and WAYLIVRA designed to prevent sudden, life-threatening attacks in patients with genetic conditions.
• Partnered Pipeline: Many experimental medicines developed with other companies that pay Ionis fees and royalties as they reach new testing stages.

Growth and Partnering Up

• Formed a joint development and commercialization agreement with AstraZeneca in 2021 to bring the medicine eplontersen to global markets.
• Expanded a commercialization agreement with Otsuka in 2024 to include rights for DAWNZERA in the Asia-Pacific region.
• Partnered with Metagenomi in 2022 to research and develop new medicines using advanced gene editing technologies.
• Entered a 2025 agreement with Ono to develop and sell sapablursen for the treatment of a rare blood disease.
• Licensed technology from Vect-Horus in 2023 to help medicines cross the blood-brain barrier and reach the central nervous system.

What Makes the Company Stand Out

Ionis maintains a leading position in RNA technology by utilizing its Ligand-Conjugated Antisense platform to deliver medicines more effectively to specific tissues like the liver. The company has transitioned from a research-focused firm into a fully integrated business that can now launch and sell its own medicines independently.

Key Financial Facts

• Total revenue was $944 million in 2025, which included royalties from global sales of SPINRAZA and QALSODY.
• Quarterly revenue for Q4 2025 was $203 million, down 10.4% from the $226.6 million reported in Q4 2024.
• The company reported a net loss of $229 million in Q4 2025, compared to a net loss of $104.3 million in Q4 2024.
• Cash, cash equivalents, and short-term investments totaled $2.7 billion at the end of 2025 to fund ongoing drug launches.
• Operating cash flow was negative $137.7 million in Q4 2025, an 18.6% increase in cash usage from the prior year.

The Evolution of Ionis

Ionis has transformed from a pioneer in RNA research into a commercial-stage company with seven marketed medicines and a broad pipeline. By balancing independent launches with major pharmaceutical partnerships, the company has built a platform capable of addressing diverse genetic diseases.